PeptidePrices safety rating
6/10 · Approved in some countries
Cerebrolysin Prices
13 vendors · 6 with an issuer-verified COA · lowest 10mg from $29.29 · checked
Where to buy Cerebrolysin: 13 vendors compared
| Vendor | Price | Actions |
|---|---|---|
| 2-test panelVerified COAJanoshik | $29.29 | Buy Cerebrolysin from CertaPeptides |
| $35.99 | Buy Cerebrolysin from ZestyRat Research | |
| 3-test panelVerified COABioViridian · Tested Jun 19, 2026 | $44.10 | Buy Cerebrolysin from Athena Peptides |
| $49.81 | Buy Cerebrolysin from Vistara Labs | |
| $50.22 | Buy Cerebrolysin from Atlas Longevity | |
| 4-test panelVerified COABioSyn Systems · Tested May 12, 2026 | $50.39 | Buy Cerebrolysin from Cenexa Labs |
| $54.00 | Buy Cerebrolysin from Axon Chems | |
| $55.08 | Buy Cerebrolysin from Pantheon Peptides | |
| 3-test panelVerified COAJanoshik · Tested Jul 2, 2026 | $59.49 | Buy Cerebrolysin from Optima Supply |
| $59.96 | Buy Cerebrolysin from ORA Labs | |
| 4-test panelVerified COAMDx BioAnalytical · Tested May 31, 2026 | $74.80 | Buy Cerebrolysin from Happy Peptides |
| $89.10 | Buy Cerebrolysin from Nationwide Peptides | |
| 2-test panelVerified COAOptima Labs | $173.8460mg packageChecked Sep 20 | Buy Cerebrolysin from Peptides Lab UK |
Tracked every day
Cerebrolysin listing prices, tracked daily
The five cheapest in-stock package prices for Cerebrolysin on each collected day, and the vendors that most often held those places.
Five cheapest in-stock package prices per day
Listed package price before coupons, any vial size. This is not the coupon-adjusted lowest 10mg price used to rank the comparison.
- Cheapest$32.54
- 2nd cheapest$49.00
- 3rd cheapest$55.80
- 4th cheapest$60.00
- 5th cheapest$61.20
Vendors most often in the cheapest five
- CertaPeptides21 days$32.54+12.2%
- Vistara Labs15 days$55.34last seen Oct 3, 20260.0%
- Axon Chems15 days$60.000.0%
- Pantheon Peptides15 days$61.200.0%
- ORA Labs13 days$74.95last seen Oct 6, 20260.0%
- Cenexa Labs7 days$62.99last seen Oct 7, 20260.0%
- Happy Peptides5 days$88.00last seen Oct 6, 20260.0%
- Alpha Carbon Labs4 days$80.00last seen Sep 24, 20260.0%
Top 8 of 10 vendors that reached the cheapest five
Current market data
Cerebrolysin Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current 10mg cost for Cerebrolysin is $29.29 from CertaPeptides. The median across vendors is $54.00.
- Lowest 10mg cost
- $29.29CertaPeptides
- Median 10mg cost
- $54.00One normalized offer per vendor
- Lowest package total
- $29.29CertaPeptides · package size may differ
- Public COA coverage
- 100%13 of 13 vendors
What the market shows
PeptidePrices found 13 in-stock listings from 13 vendors, checked through Oct 9, 2026. The lowest 10mg cost is 46% below the vendor median of $54.00; 6 vendors (46%) fall below that median. 13 of 13 vendors (100%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is Cerebrolysin? Research, safety, and status
Cerebrolysin at a glance
Mechanism
Mixture of low molecular weight neuropeptides and amino acids; mimics neurotrophic factors (BDNF, NGF, CNTF); promotes neurogenesis, synaptogenesis, and neuroprotection; BBB-penetrant.
Research areas
Cognitive enhancement; Alzheimer's disease; stroke recovery; traumatic brain injury (TBI); neuroprotection; Parkinson's; ADHD; nootropic.
Regulatory / research status
Research / preclinical only
Half-life
Complex mixture; various components. Course-based therapy rather than continuous.
Storage
Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.
Reported side effects
dizziness; rare allergic reactions. Very well-studied with good long-term safety data.
Used in Europe/Asia for stroke/TBI; some clinical trial data; not FDA-approved but prescribed widely abroad Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Study highlights
- Cerebrolysin is a standardized porcine brain-derived peptide mixture containing low-molecular-weight neuropeptides with BDNF-like and NGF-like activity; it is widely approved and used in Russia, Eastern Europe, China, and parts of Asia for stroke, vascular dementia, and Alzheimer's disease, though it lacks full regulatory approval in the US and Western Europe.
- A 2016 randomized Phase II trial (CARS) in acute ischemic stroke patients found Cerebrolysin produced significantly better upper extremity motor recovery than placebo at 90 days (effect size 0.71, p<0.0001); a 2018 meta-analysis of nine RCTs confirmed statistically significant neurological improvement at 30 days, with a number needed to treat of approximately 8.
- A 2011 randomized double-blind trial in vascular dementia showed 67.5% of Cerebrolysin-treated patients achieved combined cognitive and global improvement vs. 27.0% on placebo (p<0.0001) over 24 weeks; however, the 2020 Cochrane Review found a concerning signal of increased non-fatal serious adverse events at higher doses.
- A 2019 Cochrane systematic review on vascular dementia concluded that while cognitive function improvements were observed, the evidence quality was rated very low due to methodological limitations, and the authors cautioned that any benefits may be too small to be clinically meaningful.
Selected references
- Cerebrolysin for acute ischaemic stroke · Cochrane Database Syst Rev, 2020
- Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial · Stroke, 2016
- Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials · Neurol Sci, 2018
- Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial · J Stroke Cerebrovasc Dis, 2011
- Cerebrolysin for vascular dementia · Cochrane Database Syst Rev, 2019
- Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis · Biomed Res Int, 2017
Related pages